Holen Sie sich die Stockscreener-App
0.6522
2.34%
0.0149
Schlusskurs vom Vortag:
$0.6373
Offen:
$0.6254
24-Stunden-Volumen:
188.31K
Relative Volume:
0.23
Marktkapitalisierung:
$256.04M
Einnahmen:
$86.26M
Nettoeinkommen (Verlust:
$-50.08M
KGV:
-2.6631
EPS:
-0.2449
Netto-Cashflow:
$-94.48M
1W Leistung:
+3.20%
1M Leistung:
-12.09%
6M Leistung:
-31.91%
1J Leistung:
-50.59%
1-Tages-Spanne:
$0.6254
$0.6599
1-Wochen-Bereich:
$0.618
$0.6713
52-Wochen-Spanne:
$0.618
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Firmenname
Standard Biotools Inc
Sektor
Branche
Telefon
(650) 266-6000
Adresse
50 MILK STREET, BOSTON
Compare LAB vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.6522 | 256.04M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
98.61 | 170.62B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.39 | 119.46B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.48 | 112.95B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.14 | 63.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.72 | 50.56B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-27 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | Eingeleitet | TD Cowen | Buy |
| 2024-04-04 | Eingeleitet | Jefferies | Buy |
| 2023-07-12 | Eingeleitet | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Aktie (LAB) Neueste Nachrichten
LAB 8-K & SEC Filings - Yahoo! Finance Canada
A 1-for-20 to 1-for-40 reverse split is proposed as Standard BioTools (LAB) plans its Treeline merger. - Stock Titan
A healthcare-focused investor agrees to buy Microfluidics from Standard BioTools (LAB). - Stock Titan
A conditional sale expected to close in about 30 days would move Microfluidics out of Standard BioTools (LAB). - Stock Titan
Standard BioTools Finalizes $5.5M Mass Cytometry Business Sale to Element Biosystems - Kalkine Media
Standard BioTools Provides Update on Sale of Mass Cytometry Business - The Manila Times
Standard BioTools Inc.Common Stock (Nasdaq:LAB) Detailed Stock Data - The Chronicle-Journal
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders? - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM - PR Newswire
Treeline deal leaves Standard BioTools (NASDAQ: LAB) investors with a minority stake - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—IRDM, VRME, VAL and LAB - GlobeNewswire Inc.
INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB - Lelezard
Standard BioTools And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
Standard BioTools (LAB) Slips 1.24% to $0.65 as Tight Trading Range Takes ShapeTriple MA Cross - dars.gov.et
Standard Biotools Inc (LAB) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Standard BioTools (LAB) CEO uses 97K shares to pay taxes - Stock Titan
Standard BioTools (NASDAQ: LAB) exec uses 25.7K shares for taxes - Stock Titan
Standard BioTools (LAB) CFO sees stock withheld for taxes - Stock Titan
Standard (LAB) Session: Moves 0.73% Up to $0.65; Next Session: the Near-Term Reference Band Stretches From $0.62 to $0.68 under the Current SnapshotSentiment Shift - vinanet.vn
Enterprise value to EBIT forward of Standard BioTools Inc. – BX:FLB - TradingView
Long Focus Capital Management, LLC Adds to Standard BioTools Inc - GuruFocus
Standard BioTools (LAB) Slides 4.99% to $0.71 as Selling Pressure PersistsFactor Valuation - vinanet.vn
Standard BioTools (LAB) Slides 4.99% to $0.71 as Selling Pressure PersistsInstitutional Volume - dars.gov.et
Standard BioTools Inc (LAB) Fundamental & Financial Data - Stocktwits
Standard BioTools (LAB) holders report 7.3% stake in amended ownership filing - Stock Titan
Standard BioTools Inc.: Target Price Consensus and Analysts Recommendations | LAB | US34385P1084 - marketscreener.com
Standard BioTools Inc (LAB) sentiment score, message volume, participation score and buzz level - Stocktwits
LAB: Standard BioTools Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Standard BioTools (LAB): Long Focus Capital discloses 23.5M shares, 6% passive stake - Stock Titan
Standard BioTools (LAB) Short Interest & Short Float | Updated Aug 2026 $LAB - MarketBeat
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Standard BioTools Inc (LAB) Stock News Today - TradingKey
Standard BioTools Inc (LAB) Stock News Today - TradingKey
Is Standard BioTools Inc (LAB) Overvalued After Q2 Loss? EPS: -$0.21, Revenue: $20.1M -- GF Score: 33/100 - GuruFocus
Standard BioTools Inc. (LAB) Stock Report: Evaluating a Potential 93% Upside in the Medical Devices Sector - DirectorsTalk Interviews
Standard BioTools (LAB) Holds Steady at $0.80: Consolidation or Pivot Point Ahead?Growth Stock Picks - dars.gov.et
Standard BioTools (NasdaqGS:LAB) Stock Forecast & Analyst Predictions - Simply Wall Street
BlackRock, Inc. Reduces Standard BioTools Inc (LAB) Stake -- Sha - GuruFocus
Standard BioTools Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Standard BioTools (NASDAQ:LAB) Issues Earnings Results - MarketBeat
Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss - TradingKey
Standard BioTools Q2 revenue falls on consumables weakness - TradingView
STANDARD BIOTOOLS ($LAB) Releases Q2 2026 Earnings - Quiver Quantitative
STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary - TradingView
Standard BioTools: Q2 Earnings Snapshot - barchart.com
Standard BioTools (NASDAQ: LAB) Q2 revenue $20.1M as merger advances - Stock Titan
Standard BioTools Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Standard BioTools Reports Second Quarter 2026 Financial Results - The Manila Times
BRIEF-Standard BioTools Q2 EPS USD -0.07 - TradingView
Standard Biotools Inc. Withdraws Earnings Guidance for the Full Year 2026 - marketscreener.com
Finanzdaten der Standard Biotools Inc-Aktie (LAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Standard Biotools Inc-Aktie (LAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kim Hanjoon Alex | Chief Financial Officer |
Apr 06 '26 |
Option Exercise |
0.00 |
70,183 |
0 |
2,800,702 |
| Casdin Partners Master Fund, L | Director |
Dec 04 '25 |
Buy |
1.45 |
150,000 |
217,020 |
72,100,000 |
| Casdin Partners Master Fund, L | Director |
Dec 03 '25 |
Buy |
1.44 |
75,000 |
108,037 |
71,950,000 |
| Casdin Partners Master Fund, L | Director |
Dec 02 '25 |
Buy |
1.42 |
125,000 |
177,512 |
71,875,000 |
| Casdin Partners Master Fund, L | Director |
Nov 25 '25 |
Buy |
1.30 |
7,550,000 |
9,838,405 |
71,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 24 '25 |
Buy |
1.43 |
150,000 |
214,875 |
64,200,000 |
| Casdin Partners Master Fund, L | Director |
Nov 20 '25 |
Buy |
1.30 |
450,000 |
586,260 |
64,050,000 |
| Casdin Partners Master Fund, L | Director |
Nov 19 '25 |
Buy |
1.28 |
350,000 |
448,910 |
63,600,000 |
| Casdin Partners Master Fund, L | Director |
Nov 18 '25 |
Buy |
1.23 |
275,000 |
339,405 |
63,250,000 |
| Casdin Partners Master Fund, L | Director |
Nov 17 '25 |
Buy |
1.22 |
225,000 |
275,580 |
62,975,000 |
1.29%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):